Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The company will also share results in two additional posters for deuruxolitinib
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Subscribe To Our Newsletter & Stay Updated
